FDA 拒绝了 Capricor 治疗肌肉萎缩症的心脏疗法，理由是疗效怀疑和制造问题。 FDA rejects Capricor's heart therapy for muscular dystrophy, citing efficacy doubts and manufacturing issues.

美国食品和药物管理局拒绝批准Capricor Therapeutics的细胞疗法Deramiocel,用于治疗杜申肌力衰竭患者的心脏问题,理由是缺乏有效性和制造方面的证据. The FDA has declined to approve Capricor Therapeutics' cell therapy, Deramiocel, for treating heart issues in Duchenne muscular dystrophy patients, citing insufficient evidence of effectiveness and manufacturing concerns. 这一决定导致Capricor的股票价格大幅下降。 This decision led to a significant drop in Capricor's stock price. 该公司计划解决这些问题,并重新提交申请,同时附上今年晚些时候正在进行的试验的补充数据。 The company plans to address these issues and resubmit the application with additional data from ongoing trials later this year.